Office, F. P. Correction: Plasma cell targeting with the anti-CD38 antibody daratumumab in myalgic encephalomyelitis/chronic fatigue syndrome—A clinical pilot study. Frontiers Media S.A.
Chicago Style (17th ed.) CitationOffice, Frontiers Production. Correction: Plasma Cell Targeting with the Anti-CD38 Antibody Daratumumab in Myalgic Encephalomyelitis/chronic Fatigue Syndrome—A Clinical Pilot Study. Frontiers Media S.A.
MLA (9th ed.) CitationOffice, Frontiers Production. Correction: Plasma Cell Targeting with the Anti-CD38 Antibody Daratumumab in Myalgic Encephalomyelitis/chronic Fatigue Syndrome—A Clinical Pilot Study. Frontiers Media S.A.
Warning: These citations may not always be 100% accurate.